Newstrike Resources Ltd. Consents to Postponement of CanniMed Therapeutics' Special Shareholders' Meeting - Seite 3

Such statements and information have been made by Newstrike in reliance on certain assumptions that it believes are reasonable at this time. Completion of the arrangement is subject to a number of conditions, including but not limited to, TSXV and TSX acceptance and shareholder approval. Where applicable, the arrangement cannot close until the required shareholder approval is obtained. There can be no assurance that the proposed Plan of Arrangement will occur, or that it will occur on the terms and conditions contemplated in this news release. Accordingly, readers should not place undue reliance on the forward-looking statements and information contained in this news release. Since forward-looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties.
Actual results could differ materially from those currently anticipated due to a number of factors and risks. Readers are cautioned that the foregoing list of factors is not exhaustive. The forward-looking statements contained in this news release are made as of the date of this release and, accordingly, are subject to change after such date. Newstrike does not assume any obligation to update or revise any forward-looking statements other than as required pursuant to applicable securities laws.

Investors are cautioned that, except as disclosed in the management information circular with the Plan of Arrangement, any information released or received with respect to the Plan of Arrangement may not be accurate or complete and should not be relied upon. Trading in the securities of Newstrike and CanniMed should be considered highly speculative.

The TSX Venture Exchange has in no way passed upon the merits of the proposed transaction and has neither approved nor disapproved the contents of this news release.

PM Rendon
Director, Communications & Public Relations
Up Cannabis Inc.
365-773-5432
[e-mail]